BeOne Medicines AG (HKG:6160)
193.00
+1.50 (0.78%)
Jul 21, 2026, 4:08 PM HKT
BeOne Medicines AG Employees
BeOne Medicines AG had 12,000 employees as of March 31, 2026. The number of employees increased by 1,000 or 9.09% compared to the same quarter last year.
Employees
12,000
Change
1,000
Growth
9.09%
Revenue / Employee
3.75M HKD
Profits / Employee
335.18K HKD
Market Cap
270.72B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 12,000 | 1,000 | 9.09% | 12,000 | 0 |
| Dec 31, 2025 | 12,000 | 1,000 | 9.09% | 12,000 | 0 |
| Sep 30, 2025 | 11,000 | 1,000 | 10.00% | 11,000 | 0 |
| Jun 30, 2025 | 11,000 | 1,000 | 10.00% | 11,000 | 0 |
| Mar 31, 2025 | 11,000 | 1,000 | 10.00% | 11,000 | 0 |
| Dec 31, 2024 | 11,000 | 400 | 3.77% | 11,000 | 0 |
| Jun 30, 2024 | 10,000 | 600 | 6.38% | 10,000 | 0 |
| Mar 31, 2024 | 10,000 | 600 | 6.38% | 10,000 | 0 |
| Dec 31, 2023 | 10,600 | 1,600 | 17.78% | 10,600 | 0 |
| Mar 31, 2023 | 9,400 | 1,100 | 13.25% | 9,400 | 0 |
| Dec 31, 2022 | 9,000 | 1,000 | 12.50% | 9,000 | 0 |
| Sep 30, 2022 | 9,000 | 1,400 | 18.42% | 9,000 | 0 |
| Mar 31, 2022 | 8,300 | 2,900 | 53.70% | 8,300 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 21,435 |
| WuXi Biologics | 13,252 |
| Innovent Biologics | 7,502 |
| Genscript Biotech | 6,165 |
| 3SBio | 6,109 |
| Shanghai Henlius Biotech | 3,762 |
| Akeso | 3,761 |
| RemeGen | 3,048 |
BeOne Medicines AG News
- 4 days ago - BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5 - Business Wire
- 7 days ago - BeOne Medicines price target lowered to $403 from $409 at Barclays - TheFly
- 8 days ago - BeOne Medicines upgraded to Buy from Hold at Jefferies - TheFly
- 11 days ago - BeOne Medicines (ONC) Receives FDA Orphan Designation for Pancreatic Cancer Treatment - GuruFocus
- 11 days ago - BeOne Medicines treatment of pancreatic cancer granted orphan status - TheFly
- 13 days ago - BeOne Medicines price target raised to $416 from $413 at Truist - TheFly
- 13 days ago - BeOne Medicines price target raised to $451 from $436 at RBC Capital - TheFly
- 20 days ago - BeOne Medicines (ONC) Reports Positive Phase 3 MANGROVE Study Results - GuruFocus